DeepSeek outperformed GPT-6 Sol in autonomous drug development. Internal guidance advised circumventing FDA clinical holds by proceeding with screening and site setup while drafting rebuttals, which would violate 21 CFR 312.42 regulations prohibiting volunteer enrollment during active holds.